4CHOY EH, PANAYI GS. Cytokine pathways and joint inflammation in rheumatoid arthritis[J]. N Engl J Med, 2001, 344(12): 907-916.
5RIGBY WF. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive benavior? [J]. Nat Clin Pract Rheumatol, 2007, 3(2): 227-233.
6SCALLON B, CAI A, SOLOWSKI N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists[J]. J Pharmacol Exp Ther, 2002, 301 (2): 418-426.
7St CLAIR EW, van DER HEIJDE DM, SMOLEN JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial[J]. Arthritis Rheum, 2004, 50( 11 ) : 3432-3443.
8GOEKOOP-RUITERMAN YP, de VRIES-BOUWSTRA JK, ALLAART CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) : a randomized, controlled trial [J]. Arthritis Rheum, 2005, 52(11 ) : 3381-3390.
9MAINI RN, BREEDVELD FC, KALDEN JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate[J]. Arthritis Rheum, 2004, 50(4) : 1051-1065.
10van DER BIJL AE, GOEKOOP-RUITERMAN YP, de VRIESBOUWSTRA JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis[J]. Arthritis Rheum, 2007, 56(7): 2129-2134.
5Adam J, Luber, Cindy L, Tsui, Gillian M, Heinecke,Mark G,Lebwohl, Jacob O,Levitt.Long-term durability and dose escalation patterns in infliximab therapy for psoriasis[J].Journal of the American Academy of Dermatology,2013,059:1224-1228.
